However, most data relate to ER+/HER2- breast cancer, and while there has been research on HER2+ patients in subgroup analyses, current clinical studies have not demonstrated substantial efficacy, necessitating further investigation. This evidence concerns the gene ERBB2 and breast carcinoma.